Ro 61-8048

Catalog No.S8172 Batch:S817201

Print

Technical Data

Formula

C17H15N3O6S2
Molecular Weight 421.45 CAS No. 199666-03-0
Solubility (25°C)* In vitro DMSO 84 mg/mL (199.31 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ro 61-8048 is a high-affinity kynurenine 3-hydroxylase (KMO) inhibitor with IC50 and Ki of 37 nM and 4.8 nM, respectively.
Targets
KMO [1]
(Cell-free assay)		 KMO [1]
(Cell-free assay)
4.8 nM(Ki) 37 nM
In vivo In gerbils and rats, Ro 61-8048 (30 mg/kg, p.o.) causes kynurenine 3-hydroxylase inhibition. [1] In models of focal or global brain ischemia, Ro 61-8048 (40 mg/kg, p.o.) reduce ischemic brain damage. [2] In a hamster model of paroxysmal dyskinesia, Ro 61-8048 (150 mg/kg i.p.) significantly reduces the severity of dystonia without leading to marked central side effects. [3] addition, prenatal inhibition of the kynurenine pathway by Ro 61-8048 leads to structural changes in the hippocampus of adult rat offspring. [4]

Protocol (from reference)

Animal Study:

[1]
  • Animal Models

    Male albino rats and female gerbils

  • Dosages

    30 μmol/kg

  • Administration

    p.o.

Selleck's Ro 61-8048 has been cited by 3 publications

Modification of kynurenine pathway via inhibition of kynurenine hydroxylase attenuates surgical brain injury complications in a male rat model. [ J Neurosci Res, 2020, 98(1):155-167] PubMed: 31257634
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. [ Leukemia, 2019, 10.1038/s41375-019-0558-x] PubMed: 31462737
Blast Preconditioning Protects Retinal Ganglion Cells and Reveals Targets for Prevention of Neurodegeneration Following Blast-Mediated Traumatic Brian Injury [ Invest Ophthalmol Vis Sci, 2019, 60(13):4159-4170] PubMed: 31598627

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.